KEY MEASURES - ALLASTRAZENECA
BIOPHARMA & ONCOLOGY
Latest Stage NME's
10
#2 Ranking
Behind Novartis (14) & Pfizer(12)
NME's Approved
6
#1 Ranking
R&D Spend
$5.2B
#3 Ranking
Behind Abbive ($3.8B) & BMS ($4.2B)
STUDIES-BIOPHARMACEUTICALS
86 Total Studies
Phase 1
#2 Ranking
26/52
SUCCESSFUL
$1.8M
Average Cost
5Months
Average Study Time
Phase 2
#2 Ranking
10/26
SUCCESSFUL
$6.3M
Average Cost
14Months
Average Study Time
Phase 3
#1 Ranking
6/10
SUCCESSFUL
$87M
Average Cost
2Years 3Months
Average Study Time